ABOUT CARDIUM: Business Strategy

Building upon our core products and product candidates, our strategic goal is to develop a portfolio of medical product candidates at various stages of development and secure additional financial resources to commercialize these products in a timely and effective manner. The key elements of our strategy are to:

• Initiate the Aspire Generx^® Clinical Study for patients with advanced coronary artery disease at major medical centers in Russia in connection with commercialization plans covering the marketing and sale of Generx in the Russian Federation (and CIS);
  
  
• Seek clinical development and commercialization partners for our Generx product candidate in other newly-industrializing countries, such as India, China and Brazil, as a cost-effective front-line therapy for patients who may not have access to advanced surgical therapies, such as angioplasty/stents and coronary artery by-pass surgery;
  
  
• Commercialize our FDA-cleared Excellagen™ product for diabetic foot ulcers and other dermal wounds and develop new product extensions based on our custom formulated collagen product platform for additional tissue regeneration applications;
  
  
• Introduce product line extensions to grow our MedPodium™ modern lifestyle product platform, a portfolio of premium, science-based, easy to use nutraceuticals, metabolics and aesthetics designed to promote health and well-being;
  
  
• Continue to review acquisitions of other companies and businesses, as well as licenses covering product opportunities and technologies on favorable economic terms consistent with Cardium's long-term business strategy and track record.